Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
It’s demoralizing to know the final word in a cancer treatment plan can come from a profit-driven decision made in an insurer’s office instead of a doctor.
MedPage Today on MSN
Another B-Cell Drug for Lupus Hits the Mark
Phase III results put obinutuzumab in line for approval ...
Marie Hindee experienced a breakthrough in her 15-year battle with chronic lymphocytic leukemia and small lymphocytic lymphoma after undergoing a cutting-edge therapy at Corewell Health Beaumont ...
The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies.As ...
LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.
A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the ...
The film industry has seen many heartbreaking losses over the years. But some moments feel especially emotional when an actor passes away just before their final movie reaches audiences, turning into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results